---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060250"
form_type: "8-K"
ticker: "OM"
cik: "0001484612"
company_name: "Outset Medical, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:39:14.900796+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outset Medical Q3 revenue $30.4M (+9% YoY); net loss $46.2M; reiterates FY23 guidance ~$130M

## Summary
- Revenue $30.4M, +9% YoY; product rev $23.5M (+8.2%), service rev $6.8M (+13.4%).
- GAAP gross margin 23.6% (vs 15.6% YoY); non-GAAP 25.6% (vs 16.4% YoY). Service margin dropped to 6.8% from 37%.
- Net loss $46.2M ($0.93/share); non-GAAP net loss $35.3M ($0.71/share).
- Cash $197M as of Sept 30; operating expenses $52.6M.
- Reiterated 2023 revenue guidance ~$130M, gross margin low-20% for year, mid-20% in Q4.

## SEC filing metadata
- accession: 0000950170-23-060250
- form_type: 8-K
- ticker: OM
- cik: 0001484612
- company_name: Outset Medical, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484612/000095017023060250/0000950170-23-060250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484612/000095017023060250/om-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060250
- JSON: https://secwatch.observer/filing/0000950170-23-060250.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060250.txt

## Key facts
- Earnings Releases
  Outset Medical, Inc. reported third quarter ended September 30, 2023 results: revenue Revenue for the third quarter was $30.4 million, net income Net loss was ($46.2) million, EPS ($0.93) per share. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: Revenue for the third quarter was $30.4 million
  - Net income: Net loss was ($46.2) million
  - EPS: ($0.93) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023. Revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022, and gross margin was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484612/000095017023060250/0000950170-23-060250-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.